Abstrato

Therapeutic strategy for Novel COVID-19

Laila M. Montaser

 Statement of the Problem: As plentiful are conscious the novel COVID-19 is gripping quickly all over the globe. Scientists and clinicians anywhere are functioning as fast as they can to recognize how this novel virus works and to test to discover therapies and progress vaccines. While there are no specific treatments for COVID-19 at the moment, there is reason to test if blood-derived plasma rich in growth factors (PRGF) could help mitigate the damaging inflammation associated with COVID-19 pneumonia. Based on the positive results in animal and research studies, PRGF were already in clinical trials for the treatment of a number of conditions, even before the emergence of COVID-19. There are so many stories in the news about convalescent plasma and COVID-19 cases? The purpose: is to propose PRGF from recovered patients as a therapy for new COVID-19 patients. Methodology & Theoretical Orientation: I present a method standardized and optimized in my lab proposed as a therapy established on the thought that antibodies progressed by recuperated cases may prop the immune system of novel sick persons. The antibodies included in the plasma of blood possess the power to link to and equalize the virus that responsible for COVID-19. Findings: I expect to use the antibodies created by recovered cases as a succeeded therapy for novel sick persons, with the target of consolidation their immune systems and decreasing the riskiness of symptoms connected with the new virus. Conclusion & Significance: There is a hope that my proposed therapy could shed light on a promising remedy. The treatment might be an ideal choice to be used or combined with other immune modulating agents. I would pick up novel science from such disaster. Recommendations: I recommend the use of PRGF as a treatment to novel COVID-19. Such strategy is merit attempting.